Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Amivantamab in combination with Lazertinib showed efficacy in NSCLC

22 Nov 2021Oncology

Connie TANG

Share

This content is sponsored. It is intended for healthcare professionals only.

Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer. The most frequent genetic mutation harboured in lung adenocarcinomas occurs in the epidermal growth factor receptor (EGFR), accounting for 40-55% in Asian patients.

Amivantamab-in-combination-with-Lazertinib-showed-efficacy-in-NSCLC

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026